Qed Therapeutics, A Bridgebio Company

This study tests an oral drug called infigratinib in infants and children under 3 years old with achondroplasia, the most common form of dwarfism. The goal is to see if it safely improves growth and body proportions. The trial has several phases to find the right dose and then co…

This study watches children aged 2.5 to 17 with hypochondroplasia, a condition causing short stature, to track their growth and health over time. No treatments or drugs are given. The goal is to learn more about how the condition affects growth, body proportions, thinking skills,…